

Novel Drug Delivery Approach for Breast Cancer

Janhavi More, Rahul G Ingle*

Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (DMIHER), Deemed to be University, Wardha, Maharashtra, India.

Received: 07th July, 2024; Revised: 28th July, 2024; Accepted: 11th August, 2024; Available Online: 31st August, 2024

ABSTRACT

Bosom malignant growth, otherwise called carcinoma of the bosom tissues, is the most widely recognized disease that repeats in ladies and the main source of death around the world, guaranteeing almost 5 million lives yearly. The world's most developed regions have a higher incidence rate of BC than less developed regions. Yet, the demise rate was found to be more prominent in immature countries. Fewer curative options were discovered in approximately 7% of women under the age of 40. A reasonable system for its initial recognition and viable treatment might come from recently created imaginative conveyance innovations. In order to work on the therapy of bosom disease, the current focus of cancer research is on developing new delivery methods for chemotherapeutic medicines, such as liposome assemblies, hydrogel-based extracellular particles, dendrimer, microspheres, microbubbles, phytosomes, micelles, and nanoformulations. In order to diagnose and treat BC, numerous cutting-edge medication delivery technologies and methods are discussed in this review.

Keywords: Breast cancer, Liposomes, Dendrimers, Nanoparticles.

International Journal of Pharmaceutical Quality Assurance (2024); DOI: 10.25258/ijpqa.15.3.95

How to cite this article: More J, Ingle RG. Novel Drug Delivery Approach for Breast Cancer. International Journal of Pharmaceutical Quality Assurance. 2024;15(3):1723-1727.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Carcinoma influencing the bosom (BC) remains the biggest serious disease among females worldwide, which has expected 2,000,000 new cases moreover 5,000,000 fatalities every year, in light of a 2014 report by the IARC, the Global Organization for Exploration on Malignant Growth. In spite of the surprising advancement in diagnosing and treating disease, this stays the most elevated passing appraising kind of malignant growth. The terminal duct of the lobule unit in the breast, which is lined with epithelial cells, is where the majority of cases of breast cancer (BC) occur. These cancer cells can be categorized as *in-situ* (in the same place) or non-invasive. The terminal and draining duct parts of the lobular unit contain these tumor-causing cells in the foundation sheet.

The term "unacceptable BC" refers to the spread of cancer cells into normal tissues that are not contained within the basement membrane of the lobules. Different types of bosom malignant growth exist; for example, hurl carcinoma, carcinoma of the ductal organ, and hypersensitive mammary carcinoma. Throw carcinoma, carcinoma of the ductal organ, and hypersensitive mammary carcinoma.

Malignant growth, center, metastasis (TNM) is the strategy used to order the different phases of chest infection. The majority of obtrusive carcinomas are typically regarded as operable in the early stages. They incorporate TNM stages

I, II, and III An. Figure 1 portrays the different times of BC. Over 90% of BC cases that are found early can be treated with a medical procedure, radiation, or fundamental treatment. Early BC patients receiving legitimate consideration have five-year endurance rates above 75%. There are presently fewer healing choices accessible to BC patients. A promising approach for the initial diagnosis and potential treatment may emerge from emerging new delivery technologies. The current focus of cancer research is on developing new methods for delivering chemotherapeutic drugs used to treat BC. Figure 1 shows the various phases of breast cancer.

These unique drug conveyance frameworks incorporate hydrogels, exosomes, dendrimers, and revived iron oxide alluring nanoparticles (IONPs) in view of L-lysine (Lys) and L-phenylalanine (PhA) stacked with curcumin (Canine). As indicated by Nosrati H *et al's* report, these IONPs were delivered. The effects, loadability, biocompatibility, CUR release profile, and antitumor efficacy were the primary subjects of the study. Mongrel-stacked amino acids have altered attractive iron oxide nanoparticles (F@AAs@CUR NPs). Because the spread of free CURResults regarding the restorative effects of unbounded not entirely settled to be more prominent when compared to those of F@Lys@CUR NPs and F@PhA@CUR NPs, structures inferred by Dog through the F@ Lys@CUR NPs and F@PhA@CUR NPs isn't typically

*Author for Correspondence: rahul.pharmacy@dmher.edu.in




Figure 1: Phases of breast cancer

as rapid. A cell death test was carried out on a single breast carcinoma cell line after SF was made into a nano-transporter in mPEG-PCL. SF/mPEG-PCL micelles could turn out to be an important chest-threatening development treatment strategy later on, *ENREF_15*. The poisonousness of the little particles on the human destructive bosom cell line MCF-7 was the premise. Consequently, it is critical to for the most part dissipate the most recent data and any immense disclosures associated with BC therapy to investigate clinical consideration and legitimate affiliations.

Breast Cancers Pathophysiology

Proliferative carcinoma, also known as breast cancer, originated in breast tissue. Changes in structure, dimpling skin, and areola spillage are a few signs of bosom disease. Staining, a knot that damages and bosom tissue enlarging are potential indications of spread. Proliferative breast lesions include intraductal carcinomas, fibroadenomas, sclerosing tumors, and glandular overgrowth. Hydroxyl revolutionaries initiate injuries and add to the pathogenesis of ductal carcinoma. Since the estrogen receptor alpha is fundamental for the appropriate development of bosom tissue, the study of disease transmission of bosom malignant growth proposes that a bosom cancer-causing agent is made when estrogen is set off without musical androgen discharge. Breastfeeding reduces the likelihood of developing breast tumors thanks to its preventative effect on the level of sex hormones linked to cancer. The underlying characterization of bosom disease remembers diseases that beginning for the lobules, conduits, skin, and from a sub-atomic viewpoint, for example, expanded tumors of the epidermal development factor receptor (EGFR) and estrogen receptor-negative cancers. 2 classes exist of growths that are positive for estrogen receptors: luminal An and luminal B.

Overexpression of the estrogen or progesterone receptor in the cell nucleus can be used to identify the type of BC.¹

Bosom malignant growth strikes ladies definitely more regularly than guys. Cancer is caused by personal, environmental, genetic, and hormonal factors. According to Woo *et al.*, antimutagenic drugs may have reduced EGFR expression, resulting in the death of MCF7 BC cells. Protein debasement was the explanation of the down-guideline of EGFR. Some quality isoforms are essential for the advancement of epithelia and modified articulation of these quality isoforms can prompt carcinogenesis. As per a new report, changed quality isoform articulations have a significant impact in the improvement of BC. The starting points of bosom malignant growth are still generally obscure. Many interconnected factors, including as chemicals, the climate, sociobiology, physiology, and hereditary qualities, can influence the advancement of bosom malignant growth.²

New Medicine Delivery Methods based on Nanotechnology

In the treatment of sickness, Fixes that incorporate nanotechnology are by and large used to overhaul strength and the ability to separate and reduce versatility to numerous drugs as well as dealing with the security and effects of harmful development therapy. Liposomes, polymeric micelles, dendrimers, polymeric nanoparticles, exosomes, and polymersomes are among the most effective carriers in drug delivery systems based on nanotechnology. They are at present being completely perused up for further developed harmful development treatment.

Nanoparticles

The nanocarriers that nanoparticles, also known as ultradispersed strong supramolecular structures, are rapidly developing range in size from 10 to 1000 nm. Various new improvements have as of late arisen because of the chance of interest in Nopharmaceuticals. NPs could influence infection treatment. Dissolving, catching, epitomizing, or interfacing the meds to a NP network that goes about as a medication supply is choices. Poly (lactic-co-glycolic corrosive) [PLGA], polyethylene glycol (Stake), and altered PLGA are frequently used in the development of nanoparticles. A couple of specialists has utilized stake and PLGA to plan NPs in various examinations. Changed na no precipitation was used to create docetaxel-stacked star-molded copolymer-based NPs based on mannitol center PLGA-TPGS diblock. The resulting NPs were much more cytotoxic than the Taxotere® formulation that is currently available for purchase. This could be because of further developed epitome productivity and medication stacking. Besides, in vivo research displayed the made NPs' more conspicuous anticancer reasonability. Cholic corrosive center star-molded PLGA-based NPs, a novel polymeric nanocarrier intended to move the medicine in a controlled and supported way, brought about a fundamentally more elevated level of cytotoxicity when simvastatin was stacked into it. By incorporating into MDA-MB-231 human BC cells, created NPs stopped cancer development for a longer period of time

and, as expected, reduced the outflow of the cell cycle protein cyclin D1. This was as opposed to consummate simvastatin and straight PLGA NPs stacked with simvastatin. Also, meds like curcumin that aren't exceptionally dissolvable in water can be made more solvent with the help of NPs. Curcumin's regular transparency is fundamentally diminished by embodying it in PLGA NPs, which in like manner extends its bioavailability and cytoplasmic conveyance, which limits the G2 receptor on MCF-7 harmful development cell lines. PLGA NPs containing ASC-J9 were created to work on the bioavailability of 3,4-dimethoxyphenyl 1,7-bis(ASC-J9), which represents 5-hydroxyhepta-1,4,6-trien-3-one, which has been suggested as a means of treating BC. Cell improvement is stifled by the G2/M ruining the effect of ASC-J9 release on the telephone cycle. An extraordinary poly (lactide-co-glycolide)- D-a-tocopheryl Stake 1000 succinate was utilized to make a polymer-lipid half-breed nanosystem that was covered by a Stake fat film. Made to help the lapatinib anticancer sufficiency. By decreasing the prescription's retention through the reticuloendothelial framework (RES), delivered nanosystems have fundamentally expanded the framework's blood course time in contrast with a free drug. This, consequently, makes the prescription assemble in dangerous development tissues, enlarging its healing feasibility in the treatment of BC. According to a separate study that was recently published, F127-cl-PEI or PEG-cl-PEI nano-gels containing functional triphosphates, floxuridine, a drug known as gem, and a combination of nucleoside resemblance demonstrated faster *in vivo* cell accumulation at very low doses than free drug, and they also demonstrated comparative cell cycle annoyance and cytotoxicity *in-vitro*. An outline of meds used in nanotechnology-based prescription conveyance frameworks and their purposes in the therapy of bosom malignant growth are given in Table 1.

Dendrimer

"Dendrimers" or "dendritic polymers" are sensible nanocarriers that could be valuable to move anticancer prescriptions into development cells and accomplish the controlled appearance of the medicine molecule. These are the most remarkable NPs, made from middle and different branches, that can be used as carriers for many kinds of particles. It is the responsibility of the fanning structure to provide effective protection against the medication's initial delivery into the circulatory system. It

is a verifiable fact that many BC patients have overexpression of human EGFR-2. Therefore, for the effective treatment of BC, trastuzumab, a recombinant and refined monoclonal neutralizer, can be coordinated against this receptor. Humanized hostile to humanEGFR-2 antibody (Herceptin®) connected polyamidoamine (PAMAM) dendrimers with gold nanoparticles and gadolinium can be used for humanEGFR-2. The poly amidoamine dendrimer gathering of materials is the subject of the most assessment, yet the assortment of the construction blocks is reliably creating.³

Micelles

Polymeric micelles beat any leftover techniques with respect to sedate dauntlessness, site-expresses, and the transportation of anticancer drugs that are ineffectually dissolvable in water. Each of these factors contributes to these strategies' higher levels of remedial adequacy. Micelles, which range in size from 5 to 100 nm, are utilized as therapeutic agents or to deliver drugs that are difficult to dissolve in water. The substance is comprised of lipophilic and hydrophilic surfactants. It structures micelles at higher fixations inside a specific focus window after conglomeration and self-get together at low focuses. Micelles can work on the dissolvability of hydrophobic disease drugs. The choice of polymer and its hydrophilic and hydrophobic block polymer properties influence the formation of a micelle. The hydrophilic covering gives the medication stem steadfastness and a more long half-life in the body. Stake is the most generally utilized hydrophilic polymer because of its low harmfulness, water-solvent nature, and steric insurance. The most often involved polymers for hydrophobic focus creation are polyethers, polyesters, and polyamino acids.

Liposome Assemblies

Liposomes are circular lipid vesicles that can be made by lipids gathering and connecting with each other in a valuable way using either normal or manufactured polymers. Liposomes can likewise be made by framing lipid vesicles. Liposomes are one of the most encouraging subclasses of nanomedicines in light of the fact that they can convey chemotherapy to explicit areas, upgrading the personal satisfaction of disease patients. pH-responsive deception liposomes containing PTX were developed to increase chemotherapy's viability. The fact that these liposomes increased anticancer movement in an *in vivo* model was accounted for.

Table 1: An outline of drugs used in nanotechnology-based prescription conveyance frameworks

<i>Delivery frameworks</i>	<i>Medications</i>	<i>Uses</i>
Small-scale particles [nanoparticles]	1.Docetaxel Kemex 2.Simvotin	To transport drugs at higher levels than linear polymers. To attain a notably elevated degree of cytotoxicity
Dendrimer	1.Herceptin Hylecta 2. 5-Flucel	An antibody against humanized EGFR-2 for early cancer detection and treatment. Induce apoptosis through synergistic action.
Micelles	1.Turmeric 2.Doxorubin Hcl	Combined synergistic impact. Change multi drug resistance via reverse
Liposome assemblies	1.Taxzeme 2.Vinelbine	Boost cytotoxicity To obtain delivery that is specifically targeted
Extracellular spheres	1.Docetaxel	To regulate the intercellular transport of certain miRNAs to induce cell death

Extracellular Spheres

Exosomes are tiny spheres covered in a two-layered film of various proteins and lipids. Because of their creation, which resembles body cell piece, exosomes are nonimmunogenic in nature and can be effectively used to transport drugs. It is anticipated that various microRNAs in consolidated exosomes will successfully combat various diseases by utilizing subatomic signals. MCF-7 was used because of the higher counts of different miniature RNAs. This method for continuously recognizing and multiplexing microRNAs in an entire exosome has proven useful for identifying malignant growth problems. Antitumor activity was demonstrated by a shikonin subsidiary obtained from naphthoquinone and detached from the lithospermum. As demonstrated by CBF, none of the cellulose subordinations adversely impacted the nasal mucosa's tissues or cells.⁴

Other Delivery Systems

Hydrogels

Because they contain unique practical gatherings, hydrogel-like polymer groups possess intrinsic hydrophilic properties. Hydrogels have a lot of potential applications in the biomedical and drug fields considering their stand-out properties, which consolidate being fragile, versatile, penetrable, biocompatible, and like live tissue.⁵

Microbubble

At the phone level, the fundamental organs of the body are powerfully cooperating with an innovative construction known as a microbubble. To prevent inconveniences, the outer layer of these non-noxious and biocompatible plans should have a standard size of some place in the scope of 0.1 and 10 μm (under 50 μm), with an obliged set of methods. For to make an acoustic impedance and spread the US in to be named a distinction trained professional, microbubbles need to have a resonance resistance, disperse the US in a total greater than human tissue, and have an opening in both thickness and compressive strength from the covered up physically tissues.⁶

Microparticles

One particularly unfavourable part of the improvement of sickness is metastasis, which is the strategy through which a confined number of perilous cells move to various district of the body through the lymph structure or dissemination framework. MPs have been shown to contribute to the foundation of increased metastatic capacity in malignant growth in a variety of ways. Lattice metalloproteinases (MMPs), which can separate the extracellular framework and enable disease cells to attack and spread, have been discovered to be transported by MPs.⁷

Gene therapy

Quality quieting utilizing minimal interfering RNAs (siRNAs) and microRNAs (miRNAs) is an unavoidably notable technique for treating dangerous development. This treatment is utilized for both demonstrative and remedial (theranostics) purposes. By evolving RNA, siRNAs stop record, control hereditary

variety, and could be utilized to treat disease. By naming the dextran-covered superparamagnetic nanoparticles in the siRNA conveyance framework as imaging specialists, it is feasible to utilize a X-ray scanner to take continuous, painless pictures of the siRNA's circulation to the cancer. The siRNA-named interceded conveyance may likewise support checking and estimating the helpful result. Dissemination of siRNA is challenging due to its simple nuclease breakdown and negative charge-induced restriction of cell movement.⁸

Radiotherapy

Radiation therapy is by and large used after a mastectomy or security chest an operation (CBS) because it deals with insane common control in chest cancer. A BRCA1 change that results in elevated radiation responsiveness has moreover been represented. A lower peril of locoregional rehash has been displayed if radiation therapy is controlled after chemotherapy for covered BRCA1 inadequate malignant growth foci, which are taken out from the chest and including tissue. Due to related effects and a lack of remedial guidelines, radiotherapy has been used less frequently in TNBC. One of the main drawbacks of this radiation is its price, as it necessitates innovative technology and sophisticated equipment. Besides, it has two or three basic off-target unfriendly outcomes associated with it.⁹⁻¹¹

CONCLUSION

They are protected, precise, and genuinely effective. They could open up new therapy choices for bosom disease. Besides, they could provoke a normal strategy for early end and treatment. This article has covered the topic. These novel methods of delivering medications are able to significantly increase apoptosis and effectively limit the proliferation of cancer cells, potentially opening up new pathways for the infection's end.

ACKNOWLEDGMENT

The authors are thankful to the Datta Meghe Institute of Higher Education and Research, Wardha for their financial support.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Hani U, Rahamathulla M, Osmani RA, Kumar HY, Urolagin D, Ansari MY, Pandey K, Devi K, Yasmin S. Recent advances in novel drug delivery systems and approaches for management of breast cancer: A comprehensive review. *Journal of Drug Delivery Science and Technology*. 2020;56:101505. <https://doi.org/10.1016/j.jddst.2020.101505>
- Angahar LT. An overview of breast cancer epidemiology, risk factors, pathophysiology, and cancer risks reduction. *MOJ Biology and Medicine*. 2017;1(4):92-96. DOI: 10.15406/mojbm.2017.01.00019
- Mugundhan SL, Mohan M. Nanoscale strides: exploring innovative therapies for breast cancer treatment. *RSC advances*. 2024;14(20):14017-14040. <https://doi.org/10.1039/D4RA02639J>
- Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy

- MK, Sharma S, Habtemariam S. Nano based drug delivery systems: recent developments and future prospects. *Journal of nanobiotechnology*. 2018;16:1-33. <https://doi.org/10.1186/s12951-018-0392-8>
5. Jangjou A, Meisami AH, Jamali K, Niakan MH, Abbasi M, Shafiee M, Salehi M, Hosseinzadeh A, Amani AM, Vaez A. The promising shadow of microbubble over medical sciences: from fighting wide scope of prevalence disease to cancer eradication. *Journal of Biomedical Science*. 2021;28:1-24. <https://doi.org/10.1186/s12929-021-00744-4>
 6. Bijwar R, Tare H. Revolutionizing Medicine: Advances in Polymeric Drug Delivery Systems. *International Journal of Drug Delivery Technology*. 2024;14(1):572-580. DOI: 10.25258/ijddt.14.1.78
 7. Gong J, Jaiswal R, Dalla P, Luk F, Bebawy M. Microparticles in cancer: A review of recent developments and the potential for clinical application. *InSeminars in cell & developmental biology*. 2015;40:35-40. <https://doi.org/10.1016/j.semcd.2015.03.009>
 8. Kamle S, Sharma S, Phutane P. Spinal Muscular Atrophy, Approved Therapies and Future Prospects. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(4):1272-1278. DOI: 10.25258/ijpqa.14.4.68
 9. Okkod A, Reddy S. A Comprehensive Review of Advances in Nanoparticle-Based Cancer Therapy. *International Journal of Drug Delivery Technology*. 2024;14(2):1077-1089. DOI: 10.25258/ijddt.14.2.72
 10. Pradhan R, Dey A, Taliyan R, Puri A, Kharavtekar S, Dubey SK. Recent advances in targeted nanocarriers for the management of Triple negative breast Cancer. *Pharmaceutics*. 2023;15(1):246. <https://doi.org/10.3390/pharmaceutics15010246>
 11. Sowjanya A, Kumar GS. In-silico and In-vitro Studies on Targeting Tumor Apoptosis by Activating Caspase-3. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(3):661-670. DOI: 10.25258/ijpqa.14.3.34